8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 26, 2026·SEC
Arcadia Biosciences, Inc.(RKDA)Earnings, Financials & Key Ratios
RKDA•NASDAQ
Price updated Jun 19, 2026
AboutArcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.Show more
- Revenue$5M-3.7%
- EBITDA-$10M-181.8%
- Net Income-$2M+66.8%
- EPS (Diluted)-1.71+66.9%
- Gross Margin36.23%-12.2%
- EBITDA Margin-205.08%-192.7%
- Operating Margin-205.74%-184.5%
- Net Margin-48.15%+65.5%
- ROE-45.14%+39.3%
RKDA Key Insights
Arcadia Biosciences, Inc. (RKDA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Sales declining 9.6% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RKDA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RKDA Price & Volume
Arcadia Biosciences, Inc. (RKDA) stock price & volume — 10-year historical chart
Loading chart...
RKDA Growth Metrics
Arcadia Biosciences, Inc. (RKDA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.08%
5 Years-9.57%
3 Years-13.16%
TTM-9.53%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-362.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-361.49%
Return on Capital
10 Years-61.02%
5 Years-63.85%
3 Years-62.1%
Last Year-129.46%
RKDA Peer Comparison
Arcadia Biosciences, Inc. (RKDA) competitors in Seeds and crop genetics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PGEN | 1.45B | 4.82 | -3.42 | 146.73% | -6.47% | -17.69% | 0.24 | |
 OFIX | 381.98M | 9.45 | -4.14 | 2.85% | -7.27% | -13.44% | 0.51 | |
 SEED | 7.39M | 0.99 | -0.95 | -20.52% | -42.61% | |||
 CTVA | 52.74B | 78.56 | 49.10 | 2.92% | 6.5% | 4.62% | 0.11 | |
 FMC | 1.44B | 11.55 | -0.65 | -18.34% | -72.93% | -82.27% | 2.00 | |
 BIOX | 23.58M | 0.37 | -0.45 | -28.3% | -82.77% | -92.01% | 0.94 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 AMTX | 133.57M | 1.96 | -1.53 | -22.29% | -35.43% |
Compare RKDA vs Peers
Arcadia Biosciences, Inc. (RKDA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RKDA Income Statement
Arcadia Biosciences, Inc. (RKDA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.03M | 1.46M | 1.17M | 8.03M | 6.78M | 7.42M | 4.45M | 5.04M | 4.86M | 4.76M |
Revenue Growth % | 26.29% | -63.64% | -20.15% | 587.25% | -15.61% | 9.41% | -39.96% | 13.27% | -3.71% | -9.53% |
Cost of Goods Sold | 283K | 661K | 885K | 5.2M | 8.71M | 6.1M | 2.17M | 2.96M | 3.1M | 3.12M |
COGS % of Revenue | 7.03% | 45.15% | 75.71% | 64.71% | 128.44% | 82.25% | 48.81% | 58.73% | 63.77% | - |
Gross Profit | 3.74M▲ 0% | 803K▼ 78.5% | 284K▼ 64.6% | 2.83M▲ 898.2% | -1.93M▼ 168.0% | 1.32M▲ 168.3% | 2.28M▲ 73.1% | 2.08M▼ 8.7% | 1.76M▼ 15.5% | 1.64M▲ 0% |
Gross Margin % | 92.97% | 54.85% | 24.29% | 35.29% | -28.44% | 17.75% | 51.19% | 41.27% | 36.23% | 34.49% |
Gross Profit Growth % | 63.24% | -78.55% | -64.63% | 898.24% | -168.01% | 168.31% | 73.12% | -8.68% | -15.47% | - |
Operating Expenses | 18.06M | 17.67M | 19.66M | 15.61M | 33.6M | 15.32M | 8.38M | 5.73M | 11.76M | 11.19M |
OpEx % of Revenue | 448.53% | 1207.17% | 1682.21% | 194.34% | 495.55% | 206.58% | 188.19% | 113.58% | 241.97% | - |
Selling, General & Admin | 10.65M | 11.6M | 13.57M | 16.47M | 22.94M | 15.04M | 8.23M | 9.64M | 7M | 6.44M |
SG&A % of Revenue | 264.56% | 792.62% | 1160.56% | 204.97% | 338.32% | 202.7% | 184.87% | 191.1% | 144.11% | - |
Research & Development | 7.41M | 6.07M | 7.1M | 7.96M | 3.89M | 1.51M | 64K | 53K | 9K | 9K |
R&D % of Revenue | 183.98% | 414.55% | 607.19% | 99.08% | 57.36% | 20.34% | 1.44% | 1.05% | 0.19% | - |
Other Operating Expenses | 0 | 0 | -1M | -8.81M | 6.77M | -1.22M | 84K | -3.96M | 4.75M | 1.26M |
Operating Income | -14.31M▲ 0% | -16.87M▼ 17.8% | -19.38M▼ 14.9% | -12.78M▲ 34.1% | -35.53M▼ 178.0% | -14.01M▲ 60.6% | -6.1M▲ 56.4% | -3.65M▲ 40.2% | -9.99M▼ 174.0% | -9.55M▲ 0% |
Operating Margin % | -355.56% | -1152.32% | -1657.91% | -159.05% | -523.98% | -188.82% | -137% | -72.31% | -205.74% | -200.78% |
Operating Income Growth % | 23.12% | -17.85% | -14.88% | 34.07% | -178.02% | 60.57% | 56.44% | 40.22% | -173.99% | - |
EBITDA | -14.04M | -16.72M | -19.19M | -12.12M | -34.48M | -13.53M | -5.82M | -3.54M | -9.96M | -9.53M |
EBITDA Margin % | -348.63% | -1141.8% | -1641.32% | -150.81% | -508.57% | -182.37% | -130.56% | -70.07% | -205.08% | -200.21% |
EBITDA Growth % | 23.37% | -19.09% | -14.78% | 36.85% | -184.59% | 60.77% | 57.02% | 39.21% | -181.84% | -197.32% |
D&A (Non-Cash Add-back) | 279K | 154K | 194K | 662K | 1.04M | 479K | 287K | 113K | 32K | 27K |
EBIT | -14.93M | -13.47M | -28.87M | -6.1M | -28.75M | -15.23M | -6.02M | -7.61M | -9.99M | -9.55M |
Net Interest Income | -747K | -2.56M | -5K | -47K | -20K | 289K | 695K | 782K | 221K | 21K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 289K | 695K | 782K | 221K | 21K |
Interest Expense | 747K | 2.56M | 5K | 47K | 20K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -1.37M | 3.4M | -9.49M | 6.63M | 19.39M | 3.19M | 781K | -661K | 7.66M | 238K |
Pretax Income | -15.68M▲ 0% | -13.47M▲ 14.1% | -28.87M▼ 114.3% | -6.15M▲ 78.7% | -16.13M▼ 162.3% | -10.81M▲ 33.0% | -5.32M▲ 50.8% | -4.31M▲ 19.0% | -2.33M▲ 45.9% | -9.31M▲ 0% |
Pretax Margin % | -389.49% | -920.08% | -2469.72% | -76.55% | -237.94% | -145.78% | -119.47% | -85.41% | -47.98% | -195.78% |
Income Tax | 26K | 10K | 2K | -124K | 2K | 14K | 8K | 8K | 8K | 8K |
Effective Tax Rate % | -0.17% | -0.07% | -0.01% | 2.02% | -0.01% | -0.13% | -0.15% | -0.19% | -0.34% | -0.09% |
Net Income | -15.71M▲ 0% | -13.48M▲ 14.2% | -28.8M▼ 113.7% | -4.66M▲ 83.8% | -14.66M▼ 214.9% | -15.38M▼ 4.9% | -13.98M▲ 9.1% | -7.04M▲ 49.7% | -2.34M▲ 66.8% | -9.32M▲ 0% |
Net Margin % | -390.14% | -920.76% | -2464.07% | -57.94% | -216.22% | -207.28% | -313.9% | -139.5% | -48.15% | -195.94% |
Net Income Growth % | 19.96% | 14.18% | -113.69% | 83.84% | -214.93% | -4.88% | 9.07% | 49.66% | 66.77% | -362.45% |
Net Income (Continuing) | -15.71M | -13.48M | -28.87M | -6.03M | -16.13M | -10.83M | -5.33M | -4.32M | -2.34M | -9.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -4.78M | -8.66M | -2.72M | 0 | 0 |
Minority Interest | 0 | 0 | 621K | 827K | 103K | -133K | -138K | 0 | 0 | 0 |
EPS (Diluted) | -291.38▲ 0% | -143.16▲ 50.9% | -181.50▼ 26.8% | -24.20▲ 86.7% | -30.33▼ 25.3% | -26.05▲ 14.1% | -11.30▲ 56.6% | -5.16▲ 54.3% | -1.71▲ 66.9% | -6.81▲ 0% |
EPS Growth % | 17.65% | 50.87% | -26.78% | 86.67% | -25.33% | 14.11% | 56.62% | 54.34% | 66.86% | -361.49% |
EPS (Basic) | -291.38 | -143.16 | -181.50 | -24.20 | -30.33 | -26.05 | -11.30 | -5.16 | -1.71 | - |
Diluted Shares Outstanding | 53.91K | 94.16K | 159.08K | 248.97K | 532.01K | 599.39K | 1.24M | 1.36M | 1.37M | 1.37M |
Basic Shares Outstanding | 53.91K | 94.16K | 159.08K | 248.97K | 532.01K | 599.39K | 1.24M | 1.36M | 1.37M | 1.37M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RKDA Balance Sheet
Arcadia Biosciences, Inc. (RKDA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.05M | 22.88M | 28.44M | 31.7M | 35.39M | 25.4M | 14.97M | 9.24M | 6.36M | 5.17M |
Cash & Short-Term Investments | 13.02M | 21.82M | 25.33M | 25.67M | 28.68M | 20.64M | 11.64M | 4.24M | 4.56M | 3.72M |
Cash Only | 9.13M | 12M | 8.42M | 14.04M | 28.68M | 20.64M | 6.52M | 4.24M | 259K | 954K |
Short-Term Investments | 3.9M | 9.82M | 16.91M | 11.63M | 0 | 0 | 5.12M | 0 | 4.3M | 2.77M |
Accounts Receivable | 1.24M | 168K | 602K | 1.41M | 1.37M | 1.22M | 514K | 1.18M | 425K | 425K |
Days Sales Outstanding | 111.97 | 41.89 | 187.96 | 63.88 | 73.75 | 60.08 | 42.12 | 85.01 | 31.93 | 56.48 |
Inventory | 229K | 181K | 1.79M | 3.81M | 4.43M | 2.32M | 1.96M | 904K | 1.21M | 840K |
Days Inventory Outstanding | 295.35 | 99.95 | 739.9 | 267.62 | 185.81 | 138.86 | 328.74 | 111.36 | 142.8 | 146.32 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.21M | 858K | 1.99M | 156K | 184K |
Total Non-Current Assets | 1.52M | 1.15M | 4.13M | 15.65M | 8.53M | 3.52M | 4.73M | 4.28M | 190K | 154K |
Property, Plant & Equipment | 299K | 395K | 3.76M | 9.37M | 5.37M | 2.53M | 1.18M | 178K | 8K | 0 |
Fixed Asset Turnover | 13.46x | 3.71x | 0.31x | 0.86x | 1.26x | 2.93x | 3.79x | 28.34x | 607.25x | 475.80x |
Goodwill | 0 | 0 | 0 | 408K | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 370K | 484K | 40K | 39K | 39K | 39K | 39K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.22M | 753K | 372K | 5.51M | 2.67M | 956K | 3.52M | 4.06M | 143K | 115K |
Total Assets | 16.57M▲ 0% | 24.02M▲ 45.0% | 32.57M▲ 35.6% | 47.35M▲ 45.4% | 43.92M▼ 7.2% | 28.92M▼ 34.1% | 19.7M▼ 31.9% | 13.52M▼ 31.4% | 6.55M▼ 51.6% | 5.32M▲ 0% |
Asset Turnover | 0.24x | 0.06x | 0.04x | 0.17x | 0.15x | 0.26x | 0.23x | 0.37x | 0.74x | 0.67x |
Asset Growth % | -70.71% | 44.98% | 35.59% | 45.36% | -7.24% | -34.15% | -31.87% | -31.4% | -51.57% | -209.43% |
Total Current Liabilities | 3.52M | 3.05M | 5.71M | 6.31M | 5.04M | 4.21M | 3.59M | 2.56M | 2.06M | 1.36M |
Accounts Payable | 366K | 285K | 492K | 726K | 1.41M | 905K | 801K | 703K | 1.45M | 1.1M |
Days Payables Outstanding | 472.05 | 157.38 | 202.92 | 50.97 | 59.14 | 54.14 | 134.48 | 86.6 | 171.19 | 179.4 |
Short-Term Debt | 0 | 0 | 24K | 1.14M | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 1M | 96K | 42K | 8K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 88K | 1.58M | 306K | 263K | 264K | 296K | 634K | 483K | 606K | 263K |
Current Ratio | 4.27x | 7.49x | 4.98x | 5.02x | 7.02x | 6.03x | 4.17x | 3.61x | 3.09x | 3.79x |
Quick Ratio | 4.20x | 7.43x | 4.67x | 4.42x | 6.14x | 5.48x | 3.63x | 3.25x | 2.50x | 3.17x |
Cash Conversion Cycle | -64.73 | -15.54 | 724.95 | 280.53 | 200.42 | 144.79 | 236.37 | 109.77 | 3.54 | 23.4 |
Total Non-Current Liabilities | 5.04M | 8.15M | 18.54M | 12.48M | 7.68M | 3.81M | 3.41M | 4.73M | 347K | 1.07M |
Long-Term Debt | 0 | 0 | 107K | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 1.5M | 5.39M | 2.22M | 1.01M | 155K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3M | 8.15M | 16.94M | 4.99M | 5.46M | 2.81M | 3.26M | 4.73M | 347K | 1.07M |
Total Liabilities | 8.56M | 11.21M | 24.25M | 18.8M | 12.72M | 8.02M | 7M | 7.29M | 2.41M | 2.44M |
Total Debt | 0 | 0 | 2.24M | 9.35M | 3.29M | 2.02M | 1.01M | 155K | 0 | 0 |
Net Debt | -9.13M | -12M | -6.18M | -4.69M | -25.39M | -18.63M | -5.51M | -4.09M | -259K | -954K |
Debt / Equity | - | - | 0.27x | 0.33x | 0.11x | 0.10x | 0.08x | 0.02x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.10x |
Interest Coverage | -19.99x | -5.27x | -5773.20x | -129.85x | -1437.75x | - | - | - | - | - |
Total Equity | 8.01M▲ 0% | 12.81M▲ 60.0% | 8.33M▼ 35.0% | 28.55M▲ 242.9% | 31.2M▲ 9.3% | 20.9M▼ 33.0% | 12.7M▼ 39.2% | 6.22M▼ 51.0% | 4.14M▼ 33.5% | 2.88M▲ 0% |
Equity Growth % | -63.93% | 60.05% | -35.03% | 242.93% | 9.26% | -33% | -39.22% | -51.01% | -33.47% | -208.25% |
Book Value per Share | 148.54 | 136.10 | 52.34 | 114.68 | 58.64 | 34.87 | 10.27 | 4.56 | 3.03 | 2.11 |
Total Shareholders' Equity | 8.01M | 12.81M | 7.71M | 27.73M | 31.09M | 21.03M | 12.84M | 6.22M | 4.14M | 2.88M |
Common Stock | 42K | 45K | 49K | 54K | 63K | 65K | 65K | 65K | 65K | 66K |
Retained Earnings | -167.26M | -178.37M | -207.17M | -211.82M | -226.49M | -257.86M | -271.84M | -278.88M | -281.22M | -285.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1K | -4.8M | 1K | 0 | 0 | 0 | 101K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 621K | 827K | 103K | -133K | -138K | 0 | 0 | 0 |
RKDA Cash Flow Statement
Arcadia Biosciences, Inc. (RKDA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.96M | -13.63M | -17.2M | -30.22M | -25.87M | -13.98M | -15.29M | -9.63M | -4.74M | -4.25M |
Operating CF Margin % | -346.87% | -931.08% | -1471.17% | -376.13% | -381.53% | -188.42% | -343.38% | -190.82% | -97.55% | - |
Operating CF Growth % | 18.12% | 2.39% | -26.17% | -75.71% | 14.4% | 45.97% | -9.42% | 37.05% | 50.77% | 194.37% |
Net Income | -15.71M | -13.48M | -28.87M | -6.03M | -16.13M | -15.61M | -13.99M | -4.32M | -2.34M | -9.32M |
Depreciation & Amortization | 279K | 154K | 194K | 662K | 1.04M | 479K | 287K | 765K | 32K | 32K |
Stock-Based Compensation | 1.47M | 1.55M | 2.29M | 2.04M | 1.54M | 1.11M | 717K | 0 | 234K | 118K |
Deferred Taxes | 812K | -5.45M | 9.37M | -107K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 98K | 2.56M | -299K | -15.33M | -9.4M | -1M | 432K | -4.63M | -2.64M | 4.51M |
Working Capital Changes | -921K | 1.04M | 123K | -11.46M | -2.92M | 1.05M | -2.74M | -1.45M | -26K | 415K |
Change in Receivables | -882K | 1.07M | -437K | -1.12M | -40K | 592K | 184K | -762K | 165K | 358K |
Change in Inventory | 183K | 160K | -1.53M | -9.75M | -2.38M | 1.12M | -2.42M | 550K | -308K | 445K |
Change in Payables | 87K | 176K | 2.1M | -580K | -372K | -757K | -522K | -303K | -399K | -905K |
Cash from Investing | 47.18M | -5.97M | -8.37M | 17.28M | 16.61M | 1.42M | -4.34M | 7.34M | 750K | 250K |
Capital Expenditures | -79K | -250K | -1.48M | -2.33M | -1.01M | -72K | -5K | -2.02M | 0 | 0 |
CapEx % of Revenue | 1.96% | 17.08% | 126.35% | 29.06% | 14.85% | 0.97% | 0.11% | 39.96% | - | 0% |
Acquisitions | 4K | 10K | 705K | 2.65M | -4.25M | 569K | 569K | 334K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 4K | 10K | -689K | 8K | 19K | 920K | 115K | 4M | 750K | 250K |
Cash from Financing | -26.1M | 22.48M | 21.99M | 20.56M | 21.9M | 4.52M | 5.51M | 9K | 6K | 1.79M |
Debt Issued (Net) | -25M | 0 | -8K | 3.07M | -2.15M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 10M | 7.5M | 8M | 25.15M | 5M | 6M | 9K | 6K | 1.79M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -1.1M | 12.48M | 14.49M | 9.49M | -1.1M | -481K | -485K | 0 | 0 | 0 |
Net Change in Cash | 7.11M▲ 0% | 2.87M▼ 59.6% | -3.58M▼ 224.6% | 7.63M▲ 313.0% | 12.64M▲ 65.8% | -8.04M▼ 163.6% | -14.13M▼ 75.7% | -2.28M▲ 83.9% | -3.98M▼ 75.0% | -2.21M▲ 0% |
Free Cash Flow | -14.04M▲ 0% | -13.88M▲ 1.2% | -18.68M▼ 34.5% | -32.55M▼ 74.3% | -26.88M▲ 17.4% | -14.05M▲ 47.7% | -15.3M▼ 8.9% | -9.64M▲ 37.0% | -4.74M▲ 50.9% | -4.25M▲ 0% |
FCF Margin % | -348.83% | -948.16% | -1597.52% | -405.19% | -396.39% | -189.39% | -343.49% | -191.14% | -97.55% | -89.32% |
FCF Growth % | 18.76% | 1.16% | -34.54% | -74.31% | 17.44% | 47.72% | -8.9% | 36.97% | 50.86% | 46.93% |
FCF per Share | -260.53 | -147.42 | -117.40 | -130.75 | -50.52 | -23.44 | -12.37 | -7.07 | -3.46 | -3.11 |
FCF Conversion (FCF/Net Income) | 0.89x | 1.01x | 0.60x | 6.49x | 1.76x | 0.91x | 1.09x | 1.37x | 2.03x | 0.46x |
Interest Paid | 746K | 0 | 4K | 10K | 25K | 1K | 0 | 0 | 0 | 0 |
Taxes Paid | 2K | 34K | 2K | 1K | 1K | 0 | 0 | 0 | 0 | 0 |
RKDA Key Ratios
Arcadia Biosciences, Inc. (RKDA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -104% | -129.48% | -272.5% | -25.25% | -49.07% | -59.03% | -83.21% | -74.37% | -45.14% | -219.35% |
Return on Invested Capital (ROIC) | -48.59% | -1548.65% | -980.49% | -73.69% | -179.62% | -260.1% | -96.7% | -58.66% | -249.17% | -215.43% |
Gross Margin | 92.97% | 54.85% | 24.29% | 35.29% | -28.44% | 17.75% | 51.19% | 41.27% | 36.23% | 34.49% |
Net Margin | -390.14% | -920.76% | -2464.07% | -57.94% | -216.22% | -207.28% | -313.9% | -139.5% | -48.15% | -195.94% |
Debt / Equity | - | - | 0.27x | 0.33x | 0.11x | 0.10x | 0.08x | 0.02x | - | 0.00x |
Interest Coverage | -19.99x | -5.27x | -5773.20x | -129.85x | -1437.75x | - | - | - | - | - |
FCF Conversion | 0.89x | 1.01x | 0.60x | 6.49x | 1.76x | 0.91x | 1.09x | 1.37x | 2.03x | 0.46x |
Revenue Growth | 26.29% | -63.64% | -20.15% | 587.25% | -15.61% | 9.41% | -39.96% | 13.27% | -3.71% | -9.53% |
Related:RKDA Dividend History·RKDA Revenue History·RKDA Price History·RKDA P/E History·RKDA Financial Ratios·RKDA Institutional Holders
RKDA SEC Filings & Documents
Arcadia Biosciences, Inc. (RKDA) SEC filings — annual & quarterly reports (10-K, 10-Q)
RKDA Frequently Asked Questions
Arcadia Biosciences, Inc. (RKDA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcadia Biosciences, Inc. (RKDA) reported $4.8M in revenue for fiscal year 2025. This represents a 32% decrease from $7.0M in 2012.
Arcadia Biosciences, Inc. (RKDA) saw revenue decline by 3.7% over the past year.
Arcadia Biosciences, Inc. (RKDA) reported a net loss of $9.3M for fiscal year 2025.
Dividend & Returns
Arcadia Biosciences, Inc. (RKDA) has a return on equity (ROE) of -45.1%. Negative ROE indicates the company is unprofitable.
Arcadia Biosciences, Inc. (RKDA) had negative free cash flow of $4.3M in fiscal year 2025, likely due to heavy capital investments.